Point72 Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Point72 Asset Management's REGN Position: Q3 2026 in Review
Point72 Asset Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 124,380 shares worth $94.3M. The stake represents 0.1% of the portfolio and ranks #223 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in REGN as recently as Q1 2026.
Point72 Asset Management first reported a position in REGN in Q2 2014 and has held it in 19 quarters since. The position peaked at $203M in Q4 2025. 1,433 funds tracked by Wall St. Rank hold REGN as of Q3 2026.
- Point72 Asset Management held 124,380 shares of Regeneron Pharmaceuticals worth $94.3M as of Q3 2026.
- Regeneron Pharmaceuticals was a new Point72 Asset Management position in Q3 2026.
- Regeneron Pharmaceuticals made up 0.1% of Point72 Asset Management's portfolio in Q3 2026, its #223 holding.
- Point72 Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 19 quarters since.
- Point72 Asset Management's Regeneron Pharmaceuticals position peaked at $203M in Q4 2025.
- 1,433 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.
Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.